ABVD or BEACOPP for advanced hodgkin lymphoma

Journal of Clinical Oncology

Volumn 34, Issue 11, 2016, Pages 1167-1169

  Engert, Andreas ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; FOLLOW UP; HEMATOLOGIC DISEASE; HODGKIN DISEASE; HUMAN; INFECTION; INFECTIOUS COMPLICATION; INFERTILITY; LEUKEMIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; FEMALE; MALE; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HODGKIN DISEASE; HUMANS; MALE;

EID: 84963735556     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.8683     Document Type: Editorial

References (25)

1. DeVita VT Jr, Simon RM, Hubbard SM, et al: Curability of advanced Hodgkin's disease with chemotherapy: Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 92:587-595, 1980.
2. Bonadonna G, Valagussa P, Santoro A: Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease: A report of 8-year results. Ann Intern Med 104:739-746, 1986.
3. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992.
4. Radford JA, Rohatiner AZ, Ryder WD, et al: ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease. J Clin Oncol 20:2988-2994, 2002.
5. Gordon LI, Hong F, Fisher RI, et al: Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 31:684-691, 2013.
6. Diehl V, Franklin J, Pfreundschuh M, et al: German Hodgkin's Lymphoma Study Group: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003 [Erratum: N Engl J Med 353:744, 2005].
7. Engert A, Diehl V, Franklin J, et al: Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27:4548-4554, 2009.
8. Borchmann P, Haverkamp H, Diehl V, et al: Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: Final analysis of the HD12 trial of the German Hodgkin Study Group. J Clin Oncol 29:4234-4242, 2011.
9. Engert A, Haverkamp H, Kobe C, et al: German Hodgkin Study Group; Swiss Group for Clinical Cancer Research; Arbeitsgemeinschaft Medikamentö se Tumortherapie: Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial. Lancet 379:1791-1799, 2012.
10. Federico M, Luminari S, Iannitto E, et al: HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial: ABVD compared with BEACOPP compared with CEC for the initial treatment of patientswith advanced Hodgkin's lymphoma: Results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 27: 805-811, 2009.
11. Viviani S, Zinzani PL, Rambaldi A, et al: Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi: ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 365:203-212, 2011.
12. Carde PP, Karrasch M, Fortpied C, et al: ABVD (8 cycles) versus BEACOPP (4 escalated cycles $ 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. J Clin Oncol 30:510s, 2012 (suppl; abstr 8002).
13. Mounier N, Brice P, Bologna S, et al: Lymphoma Study Association (LYSA): ABVD (8 cycles) versus BEACOPP (4 escalated cycles$4 baseline): Final results in stage III-IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol 25:1622-1628, 2014.
14. Merli F, Luminari S, Gobbi PG, et al: Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: A study by Fondazione Italiana Linfomi. J Clin Oncol 34:1175-1181, 2016.
15. Meyer RM, Gospodarowicz MK, Connors JM, et al: National Cancer Institute of Canada Clinical Trials Group; Eastern Cooperative Oncology Group: Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23:4634-4642, 2005.
16. Meyer RM, Gospodarowicz MK, Connors JM, et al: NCIC Clinical Trials Group; Eastern Cooperative Oncology Group: ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 366:399-408, 2012.
17. Turner S, Maher EJ, Young T, et al: What are the information priorities for cancer patients involved in treatment decisions? An experienced surrogate study in Hodgkin's disease. Br J Cancer 73:222-227, 1996.
18. Kreissl S, Mueller H, Mayer A, et al: Fatigue in Hodgkin lymphoma patients: Longitudinal evaluation and curve types up to 5 years. Presented at the 56th Annual Meeting and Exposition of the American Society of Hematology, San Francisco, CA, December 6-9, 2014 (abstr854).
19. Behringer K, Görgen H, Müller H, et al: Cancer-related fatigue in Hodgkin lymphoma patients and survivors: The impact on treatment outcome and social reintegration. Lancet (in press).
20. Johnson PW, Federico M, Fossa A, et al: Response-adapted therapy based on interim FDA-PET scans in advanced Hodgkin lymphoma: First analysis of the safety of de-escalation and safety of escalation in the international RATHL study. Presented at the 13th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 17-20, 2015 (abstr008).
21. Borchmann P, Haverkamp H, Lohri A, et al: Addition of rituximab to BEACOPP escalated to improve the outcome of early interim PET positive advanced stage Hodgkin lymphoma patients: Second planned interim analysis of the HD18 study. Presented at the 56th Annual Meeting and Exposition of the American Society of Hematology, San Francisco, CA, December 6-9, 2014 (abstr500).
22. Younes A, Gopal AK, Smith SE, et al: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30:2183-2189, 2012.
23. ClinicalTrials.gov: A randomized open-label, phase 3 trial of A1AVD versus ABVD as frontline therapy in patients with advanced classical Hodgkin lymphoma. ClinicalTrials.gov identifier: NCT01712490. https://clinicaltrials.gov.
24. Borchmann P, Eichenauer DA, Pluetschow A, et al: Targeted Beacopp variants in patients with newly diagnosed advanced stage classical Hodgkin lymphoma: Final analysis of a randomized phase II study. Presented at the 57th Annual Meeting and Exposition of the American Society of Hematology, Orlando, FL, December 5-8, 2015 (abstr580).
25. Ansell SM, Lesokhin AM, Borrello I, et al: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372:311-319, 2015.